Gilead Sciences' Kite completes acquisition of Tmunity
Santa Monica: Kite, a Gilead Company has announced the completion of the previously announced transaction to acquire Tmunity Therapeutics, a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies.
The acquisition of Tmunity complements Kite’s existing in-house cell therapy research capabilities by adding additional pipeline assets, platform capabilities, and a strategic research and licensing agreement with the University of Pennsylvania (Penn).
It will provide Kite with access to pre-clinical and clinical programs, including an ‘armored’ CAR T technology platform, which potentially could be applied to a variety of CAR T’s to enhance anti-tumor activity, as well as rapid manufacturing processes. In addition, as part of the acquisition, the Tmunity founders, who remain in their roles at Penn, will also provide consulting services to Kite as senior scientific advisors.
Read also: Kite Pharma, Daiichi Sankyo revise YESCARTA CAR T-Cell Therapy licensing agreement
The University of Pennsylvania’s Carl June, Bruce Levine, James Riley, Anne Chew were each individual equity holders in Tmunity and are now paid scientific advisors to Kite. Penn was also an equity holder in Tmunity. As inventors of some of the licensed technology, Drs. June, Levine, Riley, and Chew, along with Penn, may receive additional financial benefits under the license in the future.
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.